House Bill No. 7179, also known as Public Act No. 25-171, introduces significant changes to the regulation of pharmaceutical marketing and the dispensing of veterinary drugs. It requires pharmaceutical manufacturers to register annually as marketing firms, with a registration fee of $150 and a late fee of $100 for late renewals. These firms must provide an annual list of their representatives, which will be publicly posted, and report on their activities, including contacts with practitioners and any samples or gifts provided. The bill also allows licensed veterinarians to authorize individuals to dispense prescription veterinary drugs under specific conditions, while the Commissioner of Public Health is empowered to adopt regulations to implement these provisions. Additionally, the sale of nonlegend drugs is modified to ensure they are sold only at pharmacies or through properly permitted vending machines, which must meet strict maintenance and labeling requirements.

The bill further amends laws regarding the distribution of naloxone, an opioid antagonist, by allowing individuals to distribute it through secure boxes without needing a permit, provided certain conditions are met. It modifies the permit application process for selling nonlegend drugs, allowing fee waivers for those distributing without compensation. The bill clarifies definitions related to secure boxes and outlines responsibilities for practitioners and pharmacists in distributing opioid antagonists. It also allows vending machines for opioid antagonists to be operated by certified practitioners and pharmacists, with specific requirements for signage and information display. New legal language mandates that secure boxes display necessary signage and provides immunity from civil liability for practitioners involved in opioid antagonist distribution agreements. Overall, the bill aims to enhance access to naloxone and improve safety and compliance in its distribution.

Statutes affected:
Public Act No. 25-171: 20-623, 20-624